Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the experimental vaccine G250 with or
without IL-2 can produce an immune response in patients with renal cell carcinoma who have
had all their cancer removed by surgery.